Clinical Trials Directory

Trials / Terminated

TerminatedNCT01738724

Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin

Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
14 (actual)
Sponsor
University of Sao Paulo · Academic / Other
Sex
Female
Age
35 Years – 55 Years
Healthy volunteers
Not accepted

Summary

The investigators´aim is to assess whether the progestagen dienogest reduces leiomyoma volume and its associated symptoms to the same extent as gonadotropin releasing hormone (GnRH) analogs or the progestagen desogestrel or whether it is inferior to other drugs already in use.

Detailed description

Uterine leiomyoma is a very prevalent condition among women and, although it is mainly asymptomatic, it may be related to bothersome or debilitating symptoms, such as uterine bleeding and pelvic pain or pressure. The standard treatment is surgical (hysterectomy or myomectomy), but there has been continued interest on medical treatments. Progestagens have long been used to control bleeding associated to leiomyomas, but they have not been able to decrease myoma volume. GnRH analogs are well stablished agents, capable of controlling symptoms and decreasing the tumors´volume, but their use is limited by bone loss and menopausal symptoms. A newly introduced progestagen, dienogest, has been studied to treat endometriosis, but its effects on leiomyoma are only starting to be assessed. The investigators are aiming to compare dienogest with the GnRH analog goserelin and the progestagen desogestrel in a randomized trial to see how this new treatment compares with previously used drugs and whether it is similar, inferior or superior to them on controlling leiomyoma associated symptoms and decreasing leiomyoma volume.

Conditions

Interventions

TypeNameDescription
DRUGDienogestDienogest 2mg pills daily during 6 months
DRUGGoserelinGoserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
DRUGDesogestrelDesogestrel 75mcg pills daily during six months

Timeline

Start date
2012-01-01
Primary completion
2016-12-01
Completion
2017-12-01
First posted
2012-11-30
Last updated
2020-08-13

Source: ClinicalTrials.gov record NCT01738724. Inclusion in this directory is not an endorsement.